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C-erb B-2 amplification in cystic renal disease
GUILLERMO A. HERRERA
Department of Pathology, University of Mississippi Medical Center, Jackson, Mississippi, USA
C-erb B-2 amplification in cystic renal disease. Gene amplification
(overexpression) of c-erb B-2 was tested in a variety of cystic renal
diseases, renal cell neoplasms (adenomas and carcinomas) and end
stage kidneys without cysts. C-erb B-2 encodes a receptor-like protein
that shares homology with, but is distinct from the epidermal growth
factor (EGF) receptor. A monoclonal antibody that immunoprecipitates
a protein of approximately 185 kD from a lysate of NLH/3T3 cells
transfected with the c-erb B-2 gene was utilized for testing. Simple renal
cysts, cystic renal dysplasia, autosomal recessive polycystic kidney
disease (ARPKD), and non-cystic, essentially normal kidneys failed to
show c-erb B-2 overexpression. In contrast, autosomal-dominant poly-
cystic kidney disease (ADPKD), acquired (dialysis-associated) cystic
disease (ACD), non-cystic end stage kidneys and renal cell neoplasms
revealed overexpression of c-erb B-2 with some frequency (40% or
more of cases tested). Three cystic disorders revealing c-erb B-2
overexpression also showed platelet-derived growth factors (PDGFs)
expression in similar locations (cyst lining and adjacent tubules). Other
growth factors [insulin-like growth factor (IGF-1), fibroblast growth
factor (FGF) and beta transforming growth factor (TGF/3)J were not
noted to be overexpressed in either c-erb B-2 positive or negative cystic
diseases. C-erb B-2 may be a marker related to the proliferative/growth
capabilities of selected cystic diseases, including potential for associ-
ated genesis of benign and malignant renal cell tumors.
Renal cysts are a central pathologic feature in several renal
diseases with varied etiologies. Understanding the formation of
renal cysts has received significant attention for centuries;
however, the mechanisms involved in their development and
neoplastic transformation in a number of them are not well
understood [1, 2]. The formation of cysts must be accompanied
by hyperplasia of the lining epithelium to keep pace with the
enlarging surface area of the cystic cavities. In some cases
neoplastic transformation may occur in the lining epithelium
and some cystic renal diseases are associated with renal cell
adenomas and carcinomas. Understanding of the underlying
molecular pathology of renal cystic diseases is just beginning. It
appears that elucidation of the role of associated genes and
proto-oncogenes involved may be an important issue. The role
of epidermal growth factor has been a recent line of investiga-
tion [3—5]. C-erb B-2, a closely related proto-oncogene [61, may
also play an important role.
The erb B proto-oncogene encodes a receptor-like protein
that shares homology with but is distinct from the epidermal
growth factor [6, 7]. The c-erb B-2 oncogene transcribes a
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4.8-kD messenger RNA that translates into a 185 kD protein.
The protein product of c-erb B-2 has extracellular, transmem-
brane, and intracellular domains; the intracellular domain has
tyrosine kinase activity. C-erb B-2 encodes a membrane-bound
receptor for an as yet unknown extracellular ligand that is
widely assumed to be a cellular growth factor. C-erb B-2 lies on
human chromosome 17. Amplification of the c-erb B-2 has been
demonstrated in human breast, ovarian and pancreatic carcino-
mas and some studies have suggested that c-erb B-2 amplifica-
tion may have significant prognostic implications [8—161. A
similar factor may play a pivotal role in the genesis, develop-
ment and neoplastic potential of some cystic renal conditions.
Analysis for the c-erb B-2 can be performed by immunohisto-
chemistry. Monoclonal antibodies can recognize the c-erb B-2
protein and can detect onco-protein overexpression [71.
Methods
Wedge sections (including cortex and medulla) from both
renal poles (2 each) from forty formalin fixed, paraffin-em-
bedded blocks from a variety of cystic renal diseases, end stage
kidneys, renal cell adenomas and carcinomas were routinely
sectioned and stained with hematoxylin and eosin, as well as
immunostained using an avidin-biotin peroxidase complex tech-
nique according to Hsu, Raine and Fanger [17] with a c-erb B-2
monoclonal antibody from Triton Biosciences Inc., Alameda,
California, USA. This antibody stains frozen and paraffin-
embedded tissues and cell lines overexpressing the c-erb B-2
gene. In all cases the sections included cortical and medullary
areas. Four immunostaining sections were cut at 4 microns,
deparaffinized and hydrated through xylenes and graded alco-
hols to distilled water prior to immunostaining. Sections on
slides were then incubated at 37°C for five minutes in 3%
hydrogen peroxide to block endogenous peroxidase activity in
tissues. The slides were subsequently incubated with the pri-
mary antibody (1/9 dilution) for one hour, the linking avidin-
biotin complex (ABC), and later incubated again with the
substrate (diaminobenzidine-DAB) for color development. The
sections were then counterstained with aqueous hematoxylin
and immersed in ammonia water for bluing. Below and in Table
1 are listed details pertaining to the antibody used for testing.
Hematoxylin and eosin stained sections were also prepared for
routine morphologic evaluation. At least six sections were
available for evaluation in each case. Three essentially normal,
non-cystic kidneys similarly processed, treated and immuno-
stained were also tested for evidence of c-erb B-2 amplification.
The various cystic kidneys were classified using well-described
combined histopathologic and clinical parameters following
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Table 1. Characteristics of antibodies
Antibody to Obtained from Dilution Type
C-erb B-2 Triton Biosciences, Inc.,
Alameda, California
1:9 Mouse
monoclonal
Platelet-derived Genzyme, Boston, 1:50 Mouse
growth factor A Massachusetts monoclonal
Platelet-derived Genzyme, Boston, 1:50 Mouse
growth factor B Massachusetts monoclonal
Insulin-like growth Accurate Chemical 1:50 Mouse
factor I Corporation,
Westbury, New York
monoclonal
Fibroblast growth Genzyme, Boston, 1:50 Mouse
factor Massachusetts monoclonal
Transforming Accurate Chemical 1:50 Mouse
growth factor l Corporation,
Westbury, New York
monoclonal
Bernstein criteria 118] into well recognized groups including
ARPKD, ADPKD, ACD, simple (retention) cysts and cystic
renal dysplasia.
In addition, six fresh, snap-frozen sections from kidney with
cystic and neoplastic disorders (three ACD, one simple cyst,
one ADPKD and one renal cell carcinoma) and sections from
two essentially normal (non-cystic) kidneys used as controls
were sectioned and stained using a similar immunoperoxidase
procedure as outlined above [detailed in Reference 17] and
tested for the expression of insulin-like growth factor (IGF-I),
platelet-derived growth factors (PDGFs) A and B, fibroblast
growth factor (FGF) and transforming growth factor beta
(TGF/3). The monoclonal antibodies to PDGFs A and B and
FGF were obtained from Genzyme Co. (Boston, Massachu-
setts, USA) and those to IGF-I and TGF/3 from Accurate
Chemical Co. (Westbury, New York, USA); all were used at a
1/50 dilution. Sections form both poles of the kidneys were
examined. Cryostat sections were cut at 4 microns, air dried for
10 minutes and placed in acetone for fixation. The sections were
incubated for five minutes at 37°C on a stainplate with 3%
hydrogen peroxide to block endogenous peroxidase activity in
tissues. Test samples, known positive and negative controls
were incubated for an hour with the primary antibody, the
avidin-biotin complex (ABC) and the substrate (DAB) for color
development. The slides were then counterstained with aque-
ous hematoxylin and immersed in ammonia water for bluing.
Characteristics of the antibodies, including source and dilution
used are listed in Table 1.
Characteristics of the c-erb B-2 monoclonal antibody
The monoclonal antibody c-erb B-2 immunoprecipitates a
protein of approximately 185 kD from a lysate of NIH/3T3 cells
transfected with the c-erb B-2 gene 1191, while an isotype
control antibody failed to precipitate this protein. No 185 kD
protein bands were precipitated from a non-transfected NIH!
3T3 cell lysate. This monoclonal antibody reacted with cells
overexpressing c-erb B-2 and did not immunoprecipitate EGF-
receptor protein (170 kD) from lysates of A 431 cells, nor did it
immunocytochemically stain the A 431 cell line [7, 19]. Addi-
tionally, this monoclonal antibody was shown to recognize the
external domain of the c-erb B-2 gene from radiolabeled per-
manently transfected CHO cells [71.
Table 2. C-erb B-2 expression
Specimens Number Percent
tested positive positive
Non-cystic, essentially normal kidneys 3 0 0%
Simple cysts 7 0 0%
Cystic renal dysplasia 4 0 0%
Infantile polycystic renal disease 3 0 0%
Adult polycystic renal disease 3 3 100%
Acquired cystic renal disease 8° 5 63%
End-stage renal disease without cysts 8 4 50%
Renal cell adenomas 3° 2 66%
Renal cell carcinomas 5 2 40%
Total 44 16 36%
a One case of acquired cystic renal disease also had a renal cell
adenoma (counted as one case but entered twice above).
Results
Results were evaluated in a blind fashion. C-erb B-2 amplifi-
cation was detected by immunocytochemical demonstration of
the protein product in the lining epithelium of 30% to more than
90% of the cysts and surrounding tubules in the renal cortex.
This percentage was highest for ACD (90% or more), followed
by renal cell carcinoma, (50% or more) and lowest for ADPKD
and end stage kidneys without cysts (approximately 30%). The
tubules showing c-erb B-2 overexpression were primarily prox-
imal tubules with distal tubules comprising a minority of the
positive tubules. No medullary staining was identified. The
entire cystic nephrons were similarly stained. No staining was
detected on glomeruli or in the renal vasculature. The degree of
staining was slightly variable from case to case but no repetitive
pattern could be recognized in relationship to specific condi-
tions. No attempt was made at determining the intensity of
staining, however, staining was well defined in the positive
cases. The presence or absence and the extent of staining were
the only documented findings. Staining was noted associated
with the cell membranes and also identified diffusely in the
cytoplasmic matrix of reacting cells. The staining pattern within
individual cysts was rather uniform. Two independent observ-
ers confirmed the presence and absence of staining in a double-
blind fashion. Staining was noted as detailed in Table 2, and was
present in all sections from a given case immunostained. Simple
(retention cysts), cystic renal dysplasia, ARPKD and some end
stage kidneys failed to show c-erb B-2 overexpression (Fig. 1).
However, the three ADPKD tested (Fig. 2A), 63% of ACD (Fig.
2B, 2C, 3A), 50% of end stage kidneys without cysts, 66% of
renal cell adenomas and 40% of renal cell carcinomas (Figs. 2 to
5) revealed c-erb B-2 overexpression. The one end stage kidney
with ACD and a renal adenoma showed c-erb B-2 overexpres-
sion in neoplastic areas, cysts lining and adjacent tubules (Fig.
4). The non-neoplastic renal parenchyma in cases with neo-
plasms and the non-cystic areas of c-erb B-2 positive kidneys
also showed focally c-erb B-2 overexpression in some tubules,
primarily proximal (Fig. 5). The three non-cystic, functionally
viable, essentially normal control kidneys failed to show c-erb
B-2 amplification (Fig. 1D).
Staining for PDGFs, primarily B, was noted in the cells lining
cysts and in surrounding tubules in three non-neoplastic kid-
neys (2 ACD and 1 ADPKD) and one renal cell carcinoma also
showing staining for c-erb B-2 in similar locations, however, it
was much more widespread and intense in the ACD and renal
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Fig. I. (A) Cystic dysplastic kidney, (B) simple cyst, (C) end stage kidney without cysts, (13) normal
kidney. Avidin-biotin peroxidase complex (ABC) stain for c-erb B-2. x 300. No evidence of c-erb B-2
expression is noted on any of the cystic kidneys or normal kidney illustrated.
Fig. 2. (A) Adult Onset polycystic kidney x 400 (B & C). Acquired cystic disease. Non-cystic areas X
200 (B) and cyst lining x 400 (C). Avidin-biotin peroxidase (ABC) stain for c-erb B-2. Staining for c-erb
B-2 is noted in the lining of cysts of an adult polycystic kidney (A) and in the non-cystic and cystic
areas (B & C) an end stage kidney with acquired cystic disease.
Fig. 3. Acquired cystic disease. Avidin-biotin peroxidase complex (ABC) stain for c-erb B-2 (A), and
for PDGF (B). x 300. Intense c-erb B-2 staining in cyst lining and adjacent tubules is shown in A. Same
kidney stained for PDGF shows similar staining pattern, although less intense (B). Minimal staining is
also noted in the interstitial cells.
Fig. 4. (A) Renal cell adenoma arising in acquired cystic kidney disease. (B) Adjacent cystic kidney.
Avidin-biotin peroxidase complex (ABC) stain for c-erb B-2. x 300. Staining is identified in the majority
of the neoplastic cells (A). Scattered tubules in the non-neoplastic kidney also reveal c-erb B-2
overexpression (B).
Fig. 5. Renal cell carcinoma. Avidin-biotin peroxidase (ABC) stain for c-erb B-2 (A) and for PDGF (B).
Adjacent non-neoplastic kidney c-erb B-2 (C) x 300. Staining is identified in neoplastic cells (A). PDGF
staining is also noted in tumor area. (B) Adjacent non-neoplastic kidney shows focal staining for C-erb
B-2.
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cell carcinoma (Figs. 3B, 5B). Conversely, no staining was
noted in two kidneys which failed to express c-erb B-2 (one with
ACD and one with a simple retention cyst) or in the two normal
control kidneys. No staining for IGF-I, FGF or TGFI3 was
identified in either c-erb B-2 positive or negative cystic dis-
eases, or in the two normal control kidneys. There was,
however, the expected localization of IGF-I in cortical and
medullary collecting ducts and TGF/3 in proximal tubules in
normal areas of renal parenchyma in cystic and non-cystic
control kidneys.
Discussion
C-erb B-2 encodes a protein that shares homology with but is
different from EGF. Previous studies have shown that EGF is a
mitogen for adult polycystic kidneys [3—5] and the EGF recep-
tor is located in the apical portions of the cell membranes of the
lining epithelium of the cysts. High- and low-affinity EGF
receptors have been identified in several tissues, including
kidney. In the early stages in ADPKD there appears to be an
increase in EGF receptor number and a translocation of the
high-affinity EGF receptors to the apical cell membranes [4].
Renal epithelial EGF receptors are overexpressed in renal cell
carcinomas and also in ACD associated with end-stage renal
disease (ESRD) patients on dialysis [3]. Interestingly, plasma
EGF concentration, although elevated in dialysis patients, does
not appear to correlate significantly with the presence of ACD
[3]. EGF has been noted to be increased in ACD and in ADPKD
but not in simple (retention) cysts [51. Increased sensitivity to
circulating EGF, perhaps due to overexpression of renal epi-
thelial EGF receptors, appears to be at least one of the
mechanisms operating in potentiating the growth of cysts.
Studies of c-erb B-2 have been primarily in patients with breast
cancer. C-erb B-2 amplification has been shown in some studies
to be associated with tumor behavior and has been proposed to
be a possible predictor of clinical outcome [8—IS]. It has been
suggested that c-erb B-2 may play an important role in the
pathogenesis and development not only of human breast, but
also ovarian and pancreatic tumors [15, 16, 20]. Measurement
of epidermal growth factor receptor and estrogen receptor
status have shown no significant correlation with c-erb B-2
overexpression in breast tumors [20], further emphasizing dif-
ferences between EGF and c-erb B-2.
Not much is understood about the pathogenetic mechanisms
that operate and are responsible for progressive renal injury
leading to the end stage kidney [21—26]. It is also unclear why
kidneys in patients undergoing chronic dialysis may become
cystic and are sometimes associated with cellular proliferation,
including renal cell neoplasms [21, 22, 26—28]. Factors occur-
ring during progression of renal failure and chronic dialysis
therapy result in release of autocrine and/or paracrine growth
factors that induce cell proliferation [24—26]. The specific
growth factors operating have not been entirely elucidated.
Cystic transformation in these kidneys may occur as a result of
accumulation of renotropic factors originating in viable neph-
rons, causing stimulation of the tubular epithelium leading to
cyst formation, and in some cases subsequent epithelial prolif-
erative lesions [26, 29]. Among patients with ESRD and ACD,
almost 6% have a renal neoplasm, an incidence several times
greater than the general population [26]. The actual incidence of
kidney tumors may be higher than estimated.
Cystic renal disorders and normal kidneys which are not
associated with a neoplastic propensity did not express c-erb
B-2, while some cystic disorders with associated neoplastic
potential expressed the oncogene, emphasizing the heterogene-
ity of expression in cystic diseases and the selectivity of
expression in certain restricted circumstances. The meaning of
this finding is not entirely clear at this time; however, it suggests
a possible significant role for c-erb B-2 in the pathogenesis and
growth of certain selected cystic disorders. Analysis of the
c-erb B-2 protein structure suggests that it serves as a growth
factor receptor in normal cells. The binding of an extracellular
growth factor induces the c-erb B-2 protein to send a prolifer-
ation signal to the cells.
Furthermore, testing for platelet-derived growth factors (A
and B) in a few kidneys overexpressing c-erb B-2 revealed
expression in similar locations, while PDGFs were not ex-
pressed in the c-erb B-2 negative kidneys. This finding further
supports the hypothesis that c-erb B-2 may play a role in
serving as a growth factor receptor potentiating or facilitating
the expression and execution of effector signals of other recog-
nized renal growth factors, Two types of PDGFs, A and B,
related to different receptors have been characterized. The type
B receptor, which has been cloned and sequenced, mediates the
major mitogenic effect [24]. PDGF-B expression was much
more intense than PDGF-A. Interestingly, PDGFs are usually
mitogenic in vitro primarily for mesangial cells and vessels but
not for tubular epithelial cells. The tubular action may be direct
or indirect by initially stimulating primary target cells to pro-
duce mitogenic factors which would then trigger other cells.
The demonstration of PDGFs by immunocytochemistry in
tubular cells and cysts lining suggests a direct effect.
Most of the mechanisms by which the known polypeptides
affect kidney function remain to be elucidated. Cystic renal
diseases offer a fascinating "milieu" to study the interaction of
various growth factors, as they relate to the genesis and
development of the different cystic disorders. While the accu-
mulation of growth factors that cannot be excreted may play an
important role in end stage kidneys with ACD, in other cystic
diseases there may be an oversensitivity to them (perhaps as a
result of increased number of receptors), eventually leading to
the development and progression of cysts [30]. This oversensi-
tivity is likely genetically determined in some cystic renal
disorders. It has been demonstrated, for example, that EGF is
a more potent mitogen for adult polycystic kidney than for
age-matched normal epithelia [4].
C-erb B-2 may have unique implications in the understanding
of the biologic potential of renal cystic disorders, especially as
its overexpression relates to the action of renotropic growth
factors such as PDGFs which stimulate cellular proliferation.
Epithelial proliferation, fluid accumulation, and matrix remod-
eling have been identified as the major processes in the enlarge-
ment of cysts [29]. C-erb B-2 may play a role in stimulating one
or any combination of these factors. In the case of ADPKD the
abnormal gene product could lead in some instances to the
activation of critical proto-oncogene/s within renal tubular cells
(that is, c-erb B-2) [291, which in turn may act by stimulating the
above factors through the action of selected growth factors. An
abnormal gene is not the only mechanism whereby critical
proto-oncogenes can be activated, and in the case of non-cystic
end-stage kidneys, ACD and renal cell neoplasms expressing
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c-erb B-2 other mechanisms are likely responsible (such as
endogenous or exogenous substances).
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